At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 45 enrolled
Drug / intervention
Cenicriviroc 150 mg +1 moredrug
Likely dose
Cenicriviroc 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
ORION - Effect of CCR2 and CCR5 Antagonism by Cenicriviroc on Peripheral and Adipose Tissue Insulin Sensitivity in Adult Obese Subjects With Prediabetes or Type 2 Diabetes Mellitus and Suspected Non-Alcoholic Fatty Liver Disease (NAFLD)
In Brief
A Phase 2 clinical trial evaluating Cenicriviroc 150 mg and Placebo for Prediabetic State and 2 related conditions. Completed, enrolled 45 participants across 3 sites in 2 countries.
Detailed Summary
A Phase 2a, randomized, double-blind, placebo-controlled, multi-center study of cenicriviroc (CVC) to be conducted in approximately 50 adult obese subjects \[body mass index (BMI) ≥ 30 kg/m\^2\] with prediabetes or type 2 diabetes mellitus and suspected NALFD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 2015
Enrollment StartJul 2015
Primary CompletionAug 2016
Study CompletionSep 2016
TodayJul 2026
First PostedJan 5, 2015
Enrollment StartJul 17, 2015
Primary CompletionAug 11, 2016
Study CompletionSep 8, 2016
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 11.5 years ago
Interventions
Cenicriviroc 150 mgdrug
Cenicriviroc (CVC) 150 mg, administered orally once daily and taken every morning with food.
Placebodrug
Placebo-matching CVC administered orally once daily and taken every morning with food.